Baxter International (BAX) to Release Earnings on Friday

Baxter International (NYSE:BAX) is scheduled to issue its quarterly earnings data before the market opens on Friday, November 8th. Analysts expect the company to announce earnings of $0.78 per share for the quarter. Individual interested in participating in the company’s earnings conference call can do so using this link.

Baxter International (NYSE:BAX) last posted its quarterly earnings data on Tuesday, August 6th. The medical instruments supplier reported $0.68 EPS for the quarter, beating the consensus estimate of $0.66 by $0.02. The firm had revenue of $3.81 billion during the quarter, compared to the consensus estimate of $3.75 billion. Baxter International had a return on equity of 18.06% and a net margin of 16.51%. The firm’s revenue was up 2.8% compared to the same quarter last year. During the same period in the prior year, the company earned $0.55 EPS. On average, analysts expect Baxter International to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Baxter International Trading Up 0.8 %

Shares of BAX stock opened at $36.10 on Wednesday. Baxter International has a fifty-two week low of $32.48 and a fifty-two week high of $44.01. The company has a debt-to-equity ratio of 1.35, a quick ratio of 0.91 and a current ratio of 1.40. The stock’s fifty day moving average is $37.53 and its two-hundred day moving average is $36.16. The firm has a market capitalization of $18.42 billion, a P/E ratio of 7.43, a PEG ratio of 1.21 and a beta of 0.60.

Analysts Set New Price Targets

BAX has been the topic of a number of recent research reports. Morgan Stanley lowered shares of Baxter International from an “equal weight” rating to an “underweight” rating and lowered their price target for the stock from $39.00 to $30.00 in a research report on Monday, July 15th. JPMorgan Chase & Co. dropped their price target on Baxter International from $44.00 to $42.00 and set a “neutral” rating for the company in a research report on Wednesday, August 7th. Wells Fargo & Company cut their price target on Baxter International from $44.00 to $40.00 and set an “equal weight” rating for the company in a report on Wednesday, August 7th. The Goldman Sachs Group boosted their price objective on Baxter International from $36.00 to $40.00 and gave the stock a “neutral” rating in a research note on Thursday, August 8th. Finally, Citigroup raised their target price on Baxter International from $38.00 to $40.00 and gave the stock a “neutral” rating in a research note on Tuesday, October 1st. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and three have given a buy rating to the stock. According to MarketBeat, Baxter International presently has an average rating of “Hold” and an average target price of $41.20.

About Baxter International

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.